Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | CALML3 | P27482 | 1/20 | 0.37 |
| ▸ | SDHA | P31040 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.35 |
| ▸ | AKT1 | P31749 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15141811 | 0.82 | ALDH1A1 (0.39) | MAOBGRM2MAOALMNAPTGS1 | |
| SCHEMBL14696869 | 0.80 | MAOB (0.47) | MAOBGRM2MAOALMNAPTGS1 | |
| SCHEMBL12006612 | 0.80 | MAOB (0.64) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL12006609 | 0.80 | MAOB (0.64) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL28109902 | 0.79 | MAOB (0.43) | MAOBGRM2MAOALMNAPTGS1 | |
| SCHEMBL5513931 | 0.79 | F10 (0.51) | MAOBGRM2MAOALMNAPTGS1 | |
| SCHEMBL2401267 | 0.79 | F10 (0.51) | MAOBGRM2MAOALMNAPTGS1 | |
| SCHEMBL2401271 | 0.79 | F10 (0.51) | MAOBGRM2MAOALMNAPTGS1 | |
| SCHEMBL5250497 | 0.78 | GRM2 (0.43) | MAOBGRM2MAOALMNAPTGS1 | |
| Bromide SCHEMBL2863293 | 0.78 | F10 (0.50) | MAOBGRM2MAOALMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11608320-B2 | Oxazolidinone hydroxamic acid derivatives | KUWAIT UNIVERSITY (KW) | 2023-03-21 | — | — | US | disclosed |
| US-20210238151-A1 | OXAZOLIDINONE HYDROXAMIC ACID DERIVATIVES | KUWAIT UNIVERSITY (KW) | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238151-A1 | OXAZOLIDINONE HYDROXAMIC ACID DERIVATIVES | ALOX5, ALOX15, ALOX15B | MAOB 379/4885GRM2 1343/4885MAOA 254/4885 |
| US-11608320-B2 | Oxazolidinone hydroxamic acid derivatives | ALOX5, ALOX15, ALOX15B | MAOB 375/4885GRM2 1350/4885MAOA 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.